Century Therapeutics, Inc.

NasdaqGS IPSC

Century Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2024: USD 19.82 M

Century Therapeutics, Inc. Current Liabilities is USD 19.82 M for the quarter ending September 30, 2024, a -3.01% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Century Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 20.43 M, a -24.05% change year over year.
Century Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 26.91 M, a 35.43% change year over year.
Century Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 19.87 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGS: IPSC

Century Therapeutics, Inc.

CEO	Mr. Brent Pfeiffenberger M.B.A., Pharm.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street
Employees	152
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends

Past 5 years